IL2 and neoplasm: The first involves enhancing and sustaining T cell effector functions to improve tumor cell killing, as seen in c-Jun overexpression, which enhances T cell activation, promotes IL-2 and IFN-γ secretion, reduces exhaustion markers, and collectively improves CAR-T therapy 43, 51.